• 1
    Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM. PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med 2004; 5 (Suppl 2): 6186.
  • 2
    Gazzard BG for the British HIV Association Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563608.
  • 3
    World Health Organization. Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access: Recommendations for a Public Health Approach. Geneva: World Health Organization, 2007.
  • 4
    Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Rockville, MD: National Institutes of Health, 2008.
  • 5
    Delamare C, Burgard M, Mayaux MJ et al. HIV-1 RNA detection in plasma for the diagnosis of infection in neonates. The French Pediatric HIV Infection Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15: 121125.
  • 6
    Dunn DT, Brandt CD, Krivine A et al. The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS 1995; 9: F711.
  • 7
    Nesheim S, Palumbo P, Sullivan K et al. Quantitative RNA testing for diagnosis of HIV-infected infants. J Acquir Immune Defic Syndr 2003; 32: 192195.
  • 8
    Judd A, Doerholt K, Tookey PA et al. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996–2006: planning for teenage and adult care. Clin Infect Dis 2007; 45: 918924.
  • 9
    Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. Morbid Mortal Wkly Rep 1994; 43 (RR-12): 110.
  • 10
    World Health Organization. WHO Case Definitions of HIV for Surveillance, and Revised Clinical Staging and Immunological Classification of HIV Related Disease in Adults and Children. Geneva: World Health Organization, 2006.
  • 11
    Mallal S, Phillips E, Carosi G et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568579.
  • 12
    Chintu C, Bhat GJ, Walker AS et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 2004; 364: 18651871.
  • 13
    World Health Organization. Guidelines on Co-Trimoxazole Prophylaxis for HIV-related Infections Among Children, Adolescents and Adults: Recommendations for a Public Health Approach. Geneva: World Health Organization, 2006.
  • 14
    Dunn D, Newell ML, Ades T, Peckham C, Maria ADfor the European Collaborative Study. CD4 T cell count as predictor of Pneumocystis carinii pneumonia in children born to mothers infected with HIV. BMJ 1994; 308: 437440.
  • 15
    Nachman S, Gona P, Dankner W et al. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Pediatrics 2005; 115: e488e494.
  • 16
    Urschel S, Ramos J, Mellado M et al. Withdrawal of Pneumocystis jirovecii prophylaxis in HIV-infected children under highly active antiretroviral therapy. AIDS 2005; 19: 21032108.
  • 17
    Chakraborty R, Shingadia D. Treating Opportunistic Infections in HIV-Infected Children. London: Children's HIV Association of the UK and Ireland, 2006. Available at: (accessed 2 September 2009).
  • 18
    Violari A, Cotton MF, Gibb DM et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359: 22332244.
  • 19
    Goetghebuer T, Haelterman E, Le Chenadec J et al. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS 2009; 23: 597604.
  • 20
    Dunn D, Woodburn P, Duong T et al. Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis 2008; 197: 398404.
  • 21
    El-Sadr WM, Lundgren JD, Neaton JD et al. CD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 22832296.
  • 22
    HIV Paediatric Prognostic Markers Collaborative Study Group. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 2003; 362: 16051611.
  • 23
    HIV Paediatric Prognostic Markers Collaborative Study Group. Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longitudinal data. Lancet 2005; 366: 18681874.
  • 24
    HIV Paediatric Prognostic Markers Collaborative Study Group. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS 2006; 20: 12891294.
  • 25
    Emery S for the SMART Study Group, INSIGHT. Major clinical outcomes in patients not treated with antiretroviral therapy at baseline in SMART: a rationale for a trial to examine early treatment of HIV disease. 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. Sydney, Australia, July 2007 [Abstract WEPEB018].
  • 26
    Galli L, De Martino M, Tovo PA, Gabiano C, Zappa M. Predictive value of the HIV Paediatric Classification System for the long-term course of perinatally infected children. Int J Epidemiol 2000; 29: 573578.
  • 27
    Doerholt K, Duong T, Tookey P et al. Outcomes for human immunodeficiency virus-1-infected infants in the United Kingdom and Republic of Ireland in the era of effective antiretroviral therapy. Pediatr Infect Dis J 2006; 25: 420426.
  • 28
    Phillips AN, Gazzard B, Gilson R et al. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naïve individuals with high CD4 cell count. AIDS 2007; 21: 17171721.
  • 29
    Palumbo PE, Raskino C, Fiscus S et al. Predictive value of quantitative plasma HIV RNA and CD4 lymphocyte count in HIV-infected infants and children. JAMA 1998; 279: 756761.
  • 30
    Joly V, Flandre P, Meiffredy V et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002; 16: 24472454.
  • 31
    Green H, Gibb DM, Walker AS et al. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS 2007; 21: 947955.
  • 32
    Bergshoeff A, Burger D, Verweij C et al. Plasma pharmacokinetics of once- vs. twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). Antivir Ther 2005; 10: 239246.
  • 33
    LePrevost M, Green H, Flynn J et al. Adherence and acceptability of once-daily lamivudine and abacavir in human immunodeficiency virus type-1-infected children. Pediatr Infect Dis J 2006; 25: 533537.
  • 34
    Sabin CA, Worm SW, Weber R et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371: 14171426.
  • 35
    Benson C, Ribaudo H, Zheng E et al. No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG A5001. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, February 2009 [Abstract 721].
  • 36
    Reiss P. Abacavir and Cardiovascular Risk. 16th Conference on Retroviruses and Opportunistic Infections. Montréal, Canada, February 2009 [Abstract 152].
  • 37
    Luzuriaga K, McManus M, Mofenson L, Britto P, Graham B, Sullivan JL. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med 2004; 350: 24712480.
  • 38
    Van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363: 12531263.
  • 39
    Verweel G, Sharland M, Lyall H et al. Nevirapine use in HIV-1-infected children. AIDS 2003; 17: 16391647.
  • 40
    Ruxrungtham K, Pedro R, Latiff G et al. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: Study TMC125-C227. HIV Med 2008; 9: 883896.
  • 41
    Larru B, Resino S, Bellon JM et al. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children. J Antimicrob Chemother 2008; 61: 183190.
  • 42
    Simoni JM, Montgomery A, Martin E, New M, Demas PA, Rana S. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics 2007; 119: e1371e1383.
  • 43
    Leonard EG, McComsey GA. Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J 2003; 22: 7784.
  • 44
    McComsey GA, O'Riordan M, Hazen SL et al. Increased carotid intima media thickness and cardiac biomarkers in HIV-infected children. AIDS 2007; 21: 921927.
  • 45
    Gibb D, Compagnucci A, Green H et al. Treatment interruption in children with chronic HIV-infection: the results of the Paediatric European Network for Treatment of AIDS (PENTA) 11 Trial. J Int AIDS Soc 2008; 11 (Suppl 1): O21.
  • 46
    Cressey TR, Green H, Khoo S et al. Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children. Clin Infect Dis 2008; 46: 16011608.
  • 47
    Lee KJ, Lyall EGH, Walker AS et al. Wide disparity in switch to second-line therapy in HIV-infected children in CHIPS. 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 2006 [Abstract PL 2.4].
  • 48
    Lee KJ, Shingadia D, Pillay D et al. Transient viral load increases in HIV-infected children in the UK and Ireland: what do they mean? Antivir Ther 2007; 12: 949956.